Apremilast approval expanded to include plaque psoriasis
The oral phosphodiesterase-4 inhibitor apremilast is now indicated for the treatment of moderate to severe plaque psoriasis. On Sept. 23, the manufacturer, Celgene, announced that the Food and Drug...